Analyst David Saxon from Needham reiterated a Buy rating on RxSight (RXST – Research Report) and keeping the price target at $43.00.
David Saxon has given his Buy rating due to a combination of factors including RxSight’s alignment with its revenue expectations and the reaffirmation of its financial targets for 2025. The introduction of new LDD functionality enhances the customization capabilities of their LAL products, which is anticipated to support ongoing growth. This growth is expected to be propelled by LALs, contributing to improved margins due to a favorable product mix. Considering the company’s valuation alongside its promising growth and earnings prospects, the Buy rating is reiterated.
According to TipRanks, Saxon is a 2-star analyst with an average return of 0.6% and a 36.28% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Globus Medical, Irhythm Technologies, and SI-Bone.
In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $44.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com